Because p53 is rarely mutated in ccRCC but is functionally inactivated via poorly characterized molecular mechanisms (Amendolare et al, 2022), our findings identify a novel clinically actionable gene network that may be targeted to ameliorate ccRCC response to therapies. The gene discussed is TP53; the disease is nonpapillary renal cell carcinoma.